Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

This Elite Fund’s Top Technology and Healthcare Picks Led By Apple (AAPL)

Page 1 of 2

Beech Hill Advisors, led by Paul Cantor, Joseph Weiss and Will Wurm, recently filed its 13F with the SEC, disclosing its long positions in U.S-traded equities as of September 30. Let’s take a closer look at the fund’s top picks of Alphabet Inc (NASDAQ:GOOGL), Welltower Inc (NYSE:HCN)Pfizer Inc. (NYSE:PFE)Apple Inc. (NASDAQ:AAPL), and Facebook Inc (NASDAQ:FB), and see what the investment firm likes about them, as well as what fellow elite investors think about them.


Most investors don’t understand hedge funds and indicators that are based on hedge funds’ activities. They ignore hedge funds because of their recent poor performance in the bull market. Our research indicates that hedge funds underperformed because they aren’t 100% long. Hedge fund fees are also very large compared to the returns generated and they reduce the net returns experienced by investors. We uncovered that hedge funds’ long positions actually outperformed the market. For instance the 15 most popular small-cap stocks among funds beat the S&P 500 Index by more than 53 percentage points since the end of August 2012. These stocks returned a cumulative of 102% vs. a 48.7% gain for the S&P 500 Index (see the details here). That’s why we believe investors should pay attention to what hedge funds are buying (rather than what their net returns are).

Paul Cantor, Joseph Weiss, And Will Wurm
Paul Cantor, Joseph Weiss, And Will Wurm
Beech Hill Partners

#5 Pfizer Inc. (NYSE:PFE)

Shares held (as of September 30): 169,223
Total Value (as of September 30): $5.32 million
Percent of Portfolio (as of September 30): 3.39%

The Wall Street Journal is reporting that Pfizer Inc. (NYSE:PFE) may return to its M&A roots with a potential blockbuster merger with Allergan PLC (NYSE:AGN), the maker of Botox, various biosimilars, and more than 1,000 generics and branded OTC products. If a merger between the two giants is consummated, the combined company would save on tax costs every year because Allergan is based in tax-friendly Ireland. The U.S currently has a top corporate tax rate of 35% while Ireland has a top corporate tax rate of 12.5%. Carl Icahn and U.S politicians aren’t happy about the merger, and it remains to be seen whether the management of the two firms can pull the deal off. Ken Fisher’s Fisher Asset Management owned 31.9 million shares of Pfizer at the end of September.

Follow Pfizer Inc (NYSE:PFE)
Trade (NYSE:PFE) Now!

#4 Welltower Inc (NYSE:HCN)

Shares held (as of September 30): 94,780
Total Value (as of September 30): $6.42 million
Percent of Portfolio (as of September 30): 4.09%

After rallying from $20-a-share in 2009 to $80-a-share at the beginning of 2015, shares of Welltower Inc (NYSE:HCN) are down by 9.96% year-to-date as the stock consolidates its gains and rising interest rates weigh on demand. The secular rally may not be over, however. Given the aging American population, healthcare REIT’s such as Welltower Inc (NYSE:HCN) have substantial growth opportunities over the next decade or two, as baby boomers retire into senior living communities. Jeffrey Furber‘s AEW Capital Management owned 2.2 million shares of Welltower at the end of June.

Follow Welltower Inc. (NYSE:HCN)
Trade (NYSE:HCN) Now!

Three of the biggest tech stocks in the world lead the equity portfolio of Beech Hill, as you’ll see on the next page.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!